Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 32, Issue 6, 2008, Pages 1453-1458

  Botts, Sheila ^a,b   Diaz, Francisco J ^c   Santoro, Vincenza ^d   Spina, Edoardo ^d   Muscatello, Maria R ^e   Cogollo, Myladis ^f   Castro, Fidel E ^g   de Leon, Jose ^b  

^a University of Kentucky   (United States)

^b EASTERN STATE HOSPITAL   (United States)

^c UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^d UNIVERSITY OF MESSINA   (Italy)

^e UNIVERSITY OF MESSINA   (Italy)

^f UNIVERSIDAD EAFIT   (Colombia)

^g FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

carbamazepine; Drug drug interactions; Lamotrigine; Smoking; Valproic acid

Indexed keywords

ALPRAZOLAM; ARIPIPRAZOLE; BIPERIDEN; BROMAZEPAM; CARBAMAZEPINE; CHLORPROMAZINE; CITALOPRAM; CLONAZEPAM; CLOZAPINE; DIAZEPAM; DRUG METABOLITE; DULOXETINE; ESCITALOPRAM; FLURAZEPAM; HALOPERIDOL; LAMOTRIGINE; LEVOMEPROMAZINE; LITHIUM; LORAZEPAM; MIRTAZAPINE; OLANZAPINE; OXCARBAZEPINE; RISPERIDONE; TOPIRAMATE; TRAZODONE; TRIAZOLAM; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE; ZOLPIDEM;

ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIXED MODEL; SMOKING; STATISTICAL MODEL; STEADY STATE;

ADULT; ALGORITHMS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG MONITORING; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; REGRESSION ANALYSIS; SMOKING; TRIAZINES; VALPROIC ACID;

EID: 47749087003     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2008.04.018     Document Type: Article

References (26)

1. Bergemann N., Kress K.R., Abu-Tair F., Frick A., and Kopitz J. Valproate lowers plasma concentrations of olanzapine. J Clin Psychopharm 26 (2006) 432-434
2. Botts S., Littrell R., and de Leon J. Variables associated with high olanzapine dosing in a state hospital. J Clin Psychiatry 65 (2004) 1138-1143
3. Brown H., and Prescott R. Applied mixed models in medicine (2001), John Wiley & Sons, Hoboken, NJ
4. D'Arrigo C., Migliardi G., Santoro V., and Spina E. Determination of olanzapine in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. Ther Drug Monit 28 (2006) 388-393
5. de Leon J. Glucuronidation enzymes, genes and psychiatry. Int J Neuropsychopharmacol 6 (2003) 57-72
6. de Leon J. Psychopharmacology. Atypical antipsychotic dosing: the effect of co-medication with anticonvulsants. Psychiatr Serv 55 (2004) 125-128
7. de Leon J. Psychopharmacology. Atypical antipsychotic dosing: the effect of smoking and caffeine. Psychiatr Serv 55 (2004) 491-493
8. de Leon J., Armstrong S.C., and Cozza K.L. The dosing of atypical antipsychotics. Psychosomatics 46 (2005) 262-273
9. de Leon J., Susce M.T., Johnson M., Hardin M., Pointer L., Ruaño G., et al. A clinical study of the association of antipsychotics with hyperlipidemia. Schizophr Res 92 (2007) 95-102
10. Diaz F.J., Rivera T., Josiassen R., and de Leon J. Individualizing drug dosage by using a random intercept linear model. Statist Med 26 (2007) 2052-2073
11. Diaz F.J., Santoro V., Spina E., Cogollo M., Rivera T.E., Botts S., et al. Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. Pharmacopsychiatry 41 (2008) 81-91
12. Fitzmaurice G.M., Laird N.M., and Ware J.H. Applied longitudinal analysis (2004), John Wiley & Sons, Hoboken, NJ
13. Gex-Fabry M., Balant-Gorgia A.E., and Balant L.P. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther Drug Monit 25 (2003) 46-53
14. Hiemke C., Dragicevic A., Gründer G., Hätter S., Sachse J., Vernaleken I., et al. Therapeutic monitoring of new antipsychotic drugs. Ther Drug Monit 26 (2004) 156-160
15. Jann M.W., Hon Y.Y., Shamsi S.A., Zheng J., Awad E.A., and Spratlin V. Lack of pharmacokinetic interaction between lamotrigine and olanzapine in healthy volunteers. Pharmacotherapy 26 (2006) 627-633
16. Linnet K. Glucuronidation of olanzapine by cDNA-expressed human UDP-glucuronosyltransferases and human liver microsomes. Hum Psyhcopharmacol Clin Exp 24 (2002) 512-517
17. Linnet K., and Olesen O.V. Free and glucuronidated olanzapine serum concentrations in psychiatric patients: influence of carbamazepine co-medication. Ther Drug Monit 24 (2002) 512-517
18. Littell R.C., Milliken G.A., Stroup W.W., and Wolfinger R.D. SAS for mixed models. 2nd ed (2006), SAS Institute, Inc, Cary, NC
19. Mauri M.C., Volonteri L.S., Colasanti A., Fiorentini A., De Gaspari I.F., and Bareggi S.R. Clinical pharmacokinetics of atypical antipsychotics. Clin Pharmacokinet 46 (2007) 359-388
20. Migliardi G., D'Arrigo C., Santoro V., Bruno A., Cortese L., Campolo D., et al. Effect of topiramate on plasma concentrations of clozapine, olanzapine, risperidone, and quetiapine in patients with psychotic disorders. Clin Neuropharmacol 30 (2007) 107-113
21. Muscatello M.R., Pacetti M., Cacciola M., La Torre D., Zoccali R., D'Arrigo C., et al. Plasma concentrations of risperidone and olanzapine during coadministration with oxcarbazepine. Epilepsia 46 (2005) 771-774
22. Nozawa M., Ohnuma T., Matsubara Y., Sakai Y., Hatano T., Hanzawa R., et al. The relationship between the response of clinical symptoms and plasma olanzapine concentration, Based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP). Ther Drug Monit 30 (2008) 35-40
23. Sidhu J., Job S., Bullman J., Francis E., Abbott R., Ascher J., et al. Pharmacokinetics and tolerability of lamotrigine and olanzapine coadministered to healthy subjects. Br J Clin Pharmacol 61 (2006) 420-426
24. Spina E.A., and de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Tox 100 (2007) 4-22
25. Spina E., D'Arrigo C., Migliardi G., Santoro V., Muscatello M.R., Micò U., et al. Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. Ther Drug Monit 28 (2006) 599-602
26. Zoccali R., Muscatello M.R., Torre D.L., Malara G., Canale A., Crucitti D., et al. Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia. Pharmacol Res 48 (2003) 411-414